JAN 21, 2021 8:00 AM PST

Critical reagent characterization for regulated bioassays accelerated by Uncle

Sponsored by: Unchained Labs

Event Date & Time
Date:  January 21, 2021
Time: 8:00am (PST),  11:00am (EST),  5:00pm (CET)
Today, critical reagent characterization is a key component in the overall workflow to establish robust ligand binding assays (e.g., immunoassays) for supporting the discovery and development of new biotherapeutic drugs. At B2S Life Sciences we have incorporated the Unchained Labs Uncle instrument into our comprehensive workflow to augment our detailed characterization of critical reagents. Our webinar will present two case studies where the Uncle technology provided crucial data about structural characteristics, which heretofore were not attainable by commonly used characterization methodologies, that enabled timely decision-making and decreased resource utilization. One major benefit of the Uncle is its ability to generate this key information using < 10 μL of test sample.
The first case study compares the characterization of two enzymes, where a difference in primary sequence resulted in differential aggregation behavior. Uncle DLS and Tm/Tagg data enabled selection of the correct isozyme for use in a critical assay. In the second case study we used the Uncle in early-phase drug development as the investigative tool to aid candidate selection for a series of bioconjugates. Case studies will highlight dynamic light scattering (DLS) and protein melting/aggregation (Tm/Tagg) analyses in the context of broader workflows for protein characterization.
Learning Objectives
  • How Uncle can supplement or replace more traditional characterization workflows
  • How Tm/Tagg measurements can support candidate selection or critical reagent selection
  • How the Uncle can accelerate drug development to enable efficient decision-making that results in decreased resource utilization and cost savings
Webinars will be available for unlimited on-demand viewing after live event.

You May Also Like
Loading Comments...